PML nuclear bodies: regulation, function and therapeutic perspectives
U Sahin, V Lallemand‐Breitenbach… - The Journal of …, 2014 - Wiley Online Library
U Sahin, V Lallemand‐Breitenbach, H de Thé
The Journal of pathology, 2014•Wiley Online LibraryPML nuclear bodies (NBs) were first described by electron microscopy and rediscovered
through their treatment‐reversible disruption in a rare leukaemia. They recruit multiple
partner proteins and now emerge as interferon‐and oxidative stress‐responsive
sumoylation factories. NBs mediate interferon‐induced viral restriction, enhance proteolysis,
finely tune metabolism and enforce stress‐induced senescence. Apart from being markers of
cellular stress, PML NBs could be harnessed pharmacologically in a number of conditions …
through their treatment‐reversible disruption in a rare leukaemia. They recruit multiple
partner proteins and now emerge as interferon‐and oxidative stress‐responsive
sumoylation factories. NBs mediate interferon‐induced viral restriction, enhance proteolysis,
finely tune metabolism and enforce stress‐induced senescence. Apart from being markers of
cellular stress, PML NBs could be harnessed pharmacologically in a number of conditions …
Abstract
PML nuclear bodies (NBs) were first described by electron microscopy and rediscovered through their treatment‐reversible disruption in a rare leukaemia. They recruit multiple partner proteins and now emerge as interferon‐ and oxidative stress‐responsive sumoylation factories. NBs mediate interferon‐induced viral restriction, enhance proteolysis, finely tune metabolism and enforce stress‐induced senescence. Apart from being markers of cellular stress, PML NBs could be harnessed pharmacologically in a number of conditions, including cancer, viral infection or neurodegenerative diseases. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Wiley Online Library